Hepion pharmaceuticals to be added to the russell microcap® index

Edison, n.j., june 09, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa, “hepion”), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and liver disease, is pleased to announce that it is set to join the russell microcap® index at the conclusion of the 2021 russell indexes annual reconstitution, effective after the u.s. market opens on june 28, according to a preliminary list of additions posted june 4.
HEPA Ratings Summary
HEPA Quant Ranking